Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 43 Results

Title
Intervention Indication Therapeutic Area Year Actions
LN-145 for recurrent, metastatic or persistent cervical carcinoma LN-145 Cervical cancer Female Reproductive Cancer 2020 View  |  Download
Lurbinectedin for platinum resistant ovarian cancer Lurbinectedin (PM01183; Zepzelca) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2017 View  |  Download
Mirvetuximab soravtansine for advanced, epithelial ovarian, fallopian tube, or primary peritoneal cancer with high folate receptor-alpha expression Mirvetuximab soravtansine (IMGN853) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2023 View  |  Download
Mirvetuximab Soravtansine for Platinum-resistant Ovarian Cancer Mirvetuximab soravtansine (IMGN853) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Niraparib as maintenance therapy for treating recurrent or primary-advanced endometrial cancer after chemotherapy in combination with dostarlimab. Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Niraparib for advanced ovarian, fallopian tube or primary peritoneal cancer - maintenance therapy Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Nivolumab for platinum-resistant advanced or recurrent ovarian cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2017 View  |  Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Olaparib maintenance therapy for non-gBRCA mutated high-grade serous ovarian cancer after platinum-based chemotherapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Non-gBRCA mutated high-grade serous ovarian cancer Female Reproductive Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications